Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
64.78
-0.55 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
July 19, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Topics
Death
Exposures
COVID-19
Death
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
July 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
MarketBeat Week in Review – 7/10 - 7/14
July 15, 2023
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
AbTherx Announces License Agreement with Gilead
June 07, 2023
Via
ACCESSWIRE
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
July 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
July 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
July 13, 2023
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.
Via
MarketBeat
Topics
Retirement
Exposures
Pension
3 Biotech Stocks to Buy for Long-Term Gains
July 13, 2023
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
July 13, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Nasdaq 100 Index Shake-Up Rattles High-Flying Stocks of 2023
July 12, 2023
The Nasdaq 100 index is set for a special rebalancing. Seven mega-cap stocks driving the market's gains, as well as other stocks, face weighting adjustments.
Via
MarketBeat
$1 Billion Deal For Moderna To Expand Product Pipeline in China
July 06, 2023
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher
Via
MarketBeat
Topics
ETFs
Economy
Exposures
COVID-19
Economy
Inflammatory Bowel Disease Market expected to rise | Companies – Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
June 30, 2023
Via
AB Newswire
Primary Sclerosing Cholangitis Market expected to rise | Companies – Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics
June 27, 2023
Via
AB Newswire
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
June 26, 2023
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t
Via
MarketBeat
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
June 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
June 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
June 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Alcoholic Hepatitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Durect Corporation, Novartis, Intercept Pharma, Gilead Sciences
June 16, 2023
Via
AB Newswire
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
June 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Is the Biotech Industry (IBB) Poised For A Major Breakout?
June 12, 2023
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range.
Via
MarketBeat
Topics
ETFs
2022 R&D Spending and Intensity Benchmarks
June 12, 2023
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D...
Via
PRLog
Topics
Supply Chain
Exposures
Supply Chain
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
June 08, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making...
Via
FinancialNewsMedia
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
June 06, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
June 05, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
June 05, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
June 05, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
June 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
June 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
May 26, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.